ArticleFrontiers in molecular biosciences2026
ATP-sensitive peptide-based coacervates for intracellular delivery of therapeutic oligonucleotides.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in the fields of lipoplexes, metal nanoparticles, and other nucleic acid carriers, intracellular delivery of DNA/RNA therapeutics remains a pressing area of molecular medicine. The existing delivery systems have limitations in terms of stability, efficacy, or toxicity. Peptide-based coacervates have recently emerged as a promising alternative. They offer several advantages, including easy DNA/RNA incorporation, low toxicity, and the ability to penetrate membranes. However, they have one main drawback: inefficient intracellular unpacking. In this study, we present a novel approach to programmed drug release from peptide-based coacervates. We used a previously described intrinsically disordered histidine-rich peptide as a coacervate scaffold and introduced a viral or human protein-derived ATP-responsive module into its sequence. We assembled the coacervates by mixing the resulting peptides with RNA and a model oligonucleotide (ODN), plasmid DNA, or mRNA in a pseudophysiological buffer. The admixtures of labeled peptides and ODN enabled monitoring coacervate formation and dynamics using fluorescence microscopy. The coacervates were relatively stable in ATP-free environments and underwent rearrangements involving the partial release of the ODN in the presence of ATP. The coacervates penetrated HEK293 cells within 4 hours and released the ODN into the cytoplasm within 20 h. They were inferior to the ATP-insensitive (control) peptide in delivery assays with plasmid DNA and mRNA but outperformed the control peptide in assays with the ODN. Our preliminary results suggest that ATP-sensitive coacervates have potential as ODN carriers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.